JPH11507546A - クラバム抗生物質の産生を強化する方法 - Google Patents
クラバム抗生物質の産生を強化する方法Info
- Publication number
- JPH11507546A JPH11507546A JP9502607A JP50260797A JPH11507546A JP H11507546 A JPH11507546 A JP H11507546A JP 9502607 A JP9502607 A JP 9502607A JP 50260797 A JP50260797 A JP 50260797A JP H11507546 A JPH11507546 A JP H11507546A
- Authority
- JP
- Japan
- Prior art keywords
- lat
- gene
- clabham
- pathway
- streptomyces
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000004519 manufacturing process Methods 0.000 title description 9
- 239000003242 anti bacterial agent Substances 0.000 title description 6
- 229940088710 antibiotic agent Drugs 0.000 title description 6
- 229930186147 Cephalosporin Natural products 0.000 claims abstract description 17
- 229940124587 cephalosporin Drugs 0.000 claims abstract description 17
- 150000001780 cephalosporins Chemical class 0.000 claims abstract description 17
- 230000037361 pathway Effects 0.000 claims abstract description 15
- 239000013612 plasmid Substances 0.000 claims abstract description 10
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 10
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims abstract description 8
- 238000006243 chemical reaction Methods 0.000 claims abstract description 5
- OYIFNHCXNCRBQI-BYPYZUCNSA-N L-2-aminoadipic acid Chemical compound OC(=O)[C@@H](N)CCCC(O)=O OYIFNHCXNCRBQI-BYPYZUCNSA-N 0.000 claims abstract description 4
- 235000019766 L-Lysine Nutrition 0.000 claims abstract description 4
- 239000004472 Lysine Substances 0.000 claims abstract description 4
- 101150086595 lat gene Proteins 0.000 claims description 32
- 241000187747 Streptomyces Species 0.000 claims description 18
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 claims description 16
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical group OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 claims description 16
- 229960003324 clavulanic acid Drugs 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000204 Dipeptidase 1 Proteins 0.000 claims description 3
- 102000006635 beta-lactamase Human genes 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 230000002950 deficient Effects 0.000 abstract description 2
- 101000586205 Thermococcus kodakarensis (strain ATCC BAA-918 / JCM 12380 / KOD1) Ornithine aminotransferase Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 7
- 229930182555 Penicillin Natural products 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
- 229940049954 penicillin Drugs 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 238000004166 bioassay Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- WSHJJCPTKWSMRR-RXMQYKEDSA-N penam Chemical compound S1CCN2C(=O)C[C@H]21 WSHJJCPTKWSMRR-RXMQYKEDSA-N 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- SVDOODSCHVSYEK-IFLJXUKPSA-N (4s,4ar,5s,5ar,6s,12ar)-4-(dimethylamino)-1,5,6,10,11,12a-hexahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O SVDOODSCHVSYEK-IFLJXUKPSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 108091000123 L-Lysine 6-Transaminase Proteins 0.000 description 3
- NSFFHOGKXHRQEW-UHFFFAOYSA-N Thiostrepton B Natural products N1C(=O)C(C)NC(=O)C(=C)NC(=O)C(C)NC(=O)C(C(C)CC)NC(C(C2=N3)O)C=CC2=C(C(C)O)C=C3C(=O)OC(C)C(C=2SC=C(N=2)C2N=3)NC(=O)C(N=4)=CSC=4C(C(C)(O)C(C)O)NC(=O)C(N=4)CSC=4C(=CC)NC(=O)C(C(C)O)NC(=O)C(N=4)=CSC=4C21CCC=3C1=NC(C(=O)NC(=C)C(=O)NC(=C)C(N)=O)=CS1 NSFFHOGKXHRQEW-UHFFFAOYSA-N 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- XZNUGFQTQHRASN-XQENGBIVSA-N apramycin Chemical compound O([C@H]1O[C@@H]2[C@H](O)[C@@H]([C@H](O[C@H]2C[C@H]1N)O[C@@H]1[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O1)O)NC)[C@@H]1[C@@H](N)C[C@@H](N)[C@H](O)[C@H]1O XZNUGFQTQHRASN-XQENGBIVSA-N 0.000 description 3
- 229950006334 apramycin Drugs 0.000 description 3
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 229930188070 thiostrepton Natural products 0.000 description 3
- 229940063214 thiostrepton Drugs 0.000 description 3
- NSFFHOGKXHRQEW-AIHSUZKVSA-N thiostrepton Chemical compound C([C@]12C=3SC=C(N=3)C(=O)N[C@H](C(=O)NC(/C=3SC[C@@H](N=3)C(=O)N[C@H](C=3SC=C(N=3)C(=O)N[C@H](C=3SC=C(N=3)[C@H]1N=1)[C@@H](C)OC(=O)C3=CC(=C4C=C[C@H]([C@@H](C4=N3)O)N[C@H](C(N[C@@H](C)C(=O)NC(=C)C(=O)N[C@@H](C)C(=O)N2)=O)[C@@H](C)CC)[C@H](C)O)[C@](C)(O)[C@@H](C)O)=C\C)[C@@H](C)O)CC=1C1=NC(C(=O)NC(=C)C(=O)NC(=C)C(N)=O)=CS1 NSFFHOGKXHRQEW-AIHSUZKVSA-N 0.000 description 3
- NSFFHOGKXHRQEW-OFMUQYBVSA-N thiostrepton A Natural products CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]4NC(=O)c5csc(n5)[C@@H](NC(=O)[C@H]6CSC(=N6)C(=CC)NC(=O)[C@@H](NC(=O)c7csc(n7)[C@]8(CCC(=N[C@@H]8c9csc4n9)c%10nc(cs%10)C(=O)NC(=C)C(=O)NC(=C)C(=O)N)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)[C@](C)(O)[C@@H](C)O)[C@H](C)O NSFFHOGKXHRQEW-OFMUQYBVSA-N 0.000 description 3
- 239000002132 β-lactam antibiotic Substances 0.000 description 3
- 229940124586 β-lactam antibiotics Drugs 0.000 description 3
- 241000588747 Klebsiella pneumoniae Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000001851 biosynthetic effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 239000013615 primer Substances 0.000 description 2
- 239000002987 primer (paints) Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000001938 protoplast Anatomy 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- LSRDVUINCBDNAZ-JWKOBGCHSA-N O-Carbamoyl-deacetylcephalosporin C Chemical compound S1CC(COC(N)=O)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CCC[C@@H](N)C(O)=O)[C@H]21 LSRDVUINCBDNAZ-JWKOBGCHSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000187433 Streptomyces clavuligerus Species 0.000 description 1
- 241000187398 Streptomyces lividans Species 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- UCKZMPLVLCKKMO-LHLIQPBNSA-N cephamycin Chemical compound S1CC(C)=C(C(O)=O)N2C(=O)[C@@H](C)[C@]21OC UCKZMPLVLCKKMO-LHLIQPBNSA-N 0.000 description 1
- -1 cephamycins Natural products 0.000 description 1
- 229940090805 clavulanate Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000008303 genetic mechanism Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 108010012172 isopenicillin N synthetase Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 101150118709 pcbAB gene Proteins 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 102220201851 rs143406017 Human genes 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1096—Transferases (2.) transferring nitrogenous groups (2.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Catalysts (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.セファロスポリン経路においてL−リジンのL−α−アミノアジピン酸へ の変換を妨げることにより、クラバム経路またはその一部およびセファロスポリ ン経路またはその一部の両方の経路を有する生物により産生されるクラバムの量 を増加させる方法。 2.変換工程をLAT酵素またはlat遺伝子の機能を変えることで妨げる請 求項1記載の方法。 3.lat遺伝子の機能が該遺伝子を分裂または除去することにより変えられ る請求項2記載の方法。 4.クラバムがβ−ラクタマーゼ阻害活性を有する請求項1ないし3に記載の 方法。 5.クラバムがクラブラン酸である請求項4記載の方法。 6.分裂または変異したlat遺伝子を含有する組換えプラスミド。 7.pCF002およびp486latapより選択される請求項6記載のプ ラスミド。 8.請求項1に記載の生物であって、分裂または削除されたlat遺伝子を含 有する生物。 9.ストレプトマイセス・クラブリゲラスである請求項8記載の生物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9511679.4 | 1995-06-09 | ||
GBGB9511679.4A GB9511679D0 (en) | 1995-06-09 | 1995-06-09 | Novel process |
PCT/EP1996/002497 WO1996041886A1 (en) | 1995-06-09 | 1996-06-06 | Process to increase the production of clavam antibiotics |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007140125A Division JP2007289193A (ja) | 1995-06-09 | 2007-05-28 | クラバム抗生物質の産生を強化する方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11507546A true JPH11507546A (ja) | 1999-07-06 |
JP3996640B2 JP3996640B2 (ja) | 2007-10-24 |
Family
ID=10775768
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50260797A Expired - Lifetime JP3996640B2 (ja) | 1995-06-09 | 1996-06-06 | クラバム抗生物質の産生を強化する方法 |
JP2007140125A Pending JP2007289193A (ja) | 1995-06-09 | 2007-05-28 | クラバム抗生物質の産生を強化する方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007140125A Pending JP2007289193A (ja) | 1995-06-09 | 2007-05-28 | クラバム抗生物質の産生を強化する方法 |
Country Status (12)
Country | Link |
---|---|
US (1) | US6171814B1 (ja) |
EP (1) | EP0832247B1 (ja) |
JP (2) | JP3996640B2 (ja) |
KR (2) | KR100439081B1 (ja) |
AT (1) | ATE283362T1 (ja) |
AU (1) | AU6301796A (ja) |
CA (1) | CA2221518C (ja) |
DE (1) | DE69633921T2 (ja) |
ES (1) | ES2233969T3 (ja) |
GB (1) | GB9511679D0 (ja) |
HK (1) | HK1010087A1 (ja) |
WO (1) | WO1996041886A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1228218A2 (en) * | 1999-10-22 | 2002-08-07 | Smithkline Beecham Plc | 5r clavam producing microorganisms with deleted lat and cvm genes |
GB0402799D0 (en) * | 2004-02-09 | 2004-03-10 | Sandoz Ag | Pharmaceutical composition |
CN100355895C (zh) * | 2004-12-17 | 2007-12-19 | 天津科技大学 | 棒状链霉菌lat基因缺失的质粒、衍生物及其构建方法 |
EP2589663A1 (en) | 2011-11-04 | 2013-05-08 | LEK Pharmaceuticals d.d. | Process for production of clavulanic acid |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8813055D0 (en) * | 1988-06-02 | 1988-07-06 | Beecham Group Plc | Novel substance |
EP0467049A1 (en) * | 1990-07-16 | 1992-01-22 | American Cyanamid Company | DNA sequences and amino acid sequences of class b beta-lactamase enzymes from bacteroides fragilis |
GB9302041D0 (en) | 1993-02-02 | 1993-03-17 | Smithkline Peecham P L C | Novel compounds |
US5474912A (en) * | 1994-03-03 | 1995-12-12 | Sherman; David H. | Method for increasing production of microbial metabolites by genetic engineering |
CA2182951A1 (en) * | 1994-03-03 | 1995-09-08 | Juan F. Martin | A method of transformation of nocardia |
-
1995
- 1995-06-09 GB GBGB9511679.4A patent/GB9511679D0/en active Pending
-
1996
- 1996-06-06 CA CA002221518A patent/CA2221518C/en not_active Expired - Lifetime
- 1996-06-06 DE DE69633921T patent/DE69633921T2/de not_active Expired - Lifetime
- 1996-06-06 AU AU63017/96A patent/AU6301796A/en not_active Abandoned
- 1996-06-06 EP EP96921954A patent/EP0832247B1/en not_active Expired - Lifetime
- 1996-06-06 AT AT96921954T patent/ATE283362T1/de not_active IP Right Cessation
- 1996-06-06 KR KR1019970709202A patent/KR100439081B1/ko not_active IP Right Cessation
- 1996-06-06 WO PCT/EP1996/002497 patent/WO1996041886A1/en active IP Right Grant
- 1996-06-06 US US08/981,072 patent/US6171814B1/en not_active Expired - Lifetime
- 1996-06-06 JP JP50260797A patent/JP3996640B2/ja not_active Expired - Lifetime
- 1996-06-06 KR KR10-2004-7000216A patent/KR100468932B1/ko not_active IP Right Cessation
- 1996-06-06 ES ES96921954T patent/ES2233969T3/es not_active Expired - Lifetime
-
1998
- 1998-09-24 HK HK98110939A patent/HK1010087A1/xx not_active IP Right Cessation
-
2007
- 2007-05-28 JP JP2007140125A patent/JP2007289193A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
GB9511679D0 (en) | 1995-08-02 |
WO1996041886A1 (en) | 1996-12-27 |
AU6301796A (en) | 1997-01-09 |
KR20040010848A (ko) | 2004-01-31 |
CA2221518C (en) | 2009-01-06 |
ATE283362T1 (de) | 2004-12-15 |
CA2221518A1 (en) | 1996-12-27 |
KR19990022760A (ko) | 1999-03-25 |
HK1010087A1 (en) | 1999-06-11 |
US6171814B1 (en) | 2001-01-09 |
DE69633921D1 (de) | 2004-12-30 |
EP0832247B1 (en) | 2004-11-24 |
JP3996640B2 (ja) | 2007-10-24 |
KR100439081B1 (ko) | 2004-07-16 |
KR100468932B1 (ko) | 2005-02-02 |
JP2007289193A (ja) | 2007-11-08 |
EP0832247A1 (en) | 1998-04-01 |
ES2233969T3 (es) | 2005-06-16 |
DE69633921T2 (de) | 2005-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Liras | Biosynthesis and molecular genetics of cephamycins | |
UA76690C2 (uk) | Дріжджі, що зброджують ксилозу у етанол (варіанти), плазмідний вектор та спосіб зброджування ксилози у етанол | |
JPH0691827B2 (ja) | 新規ベクタ−プラスミド | |
KR101947945B1 (ko) | L-아미노산을 생산하는 코리네박테리움 속 미생물 및 이를 이용한 l-아미노산의 생산방법 | |
JP5042186B2 (ja) | 多量のクラブラン酸を産生する微生物 | |
JPH01265892A (ja) | L−トリプトファンの製造法 | |
JP2007289193A6 (ja) | クラバム抗生物質の産生を強化する方法 | |
JP2007289193A (ja) | クラバム抗生物質の産生を強化する方法 | |
RU2652877C1 (ru) | Способ модификации дрожжей Schizosaccharomyces pombe с помощью Cre-lox системы бактериофага Р1, трансформант, полученный таким способом, и способ микробиологического синтеза молочной кислоты | |
Hung et al. | Enhancement of clavulanic acid by replicative and integrative expression of ccaR and cas2 in Streptomyces clavuligerus NRRL3585 | |
US5096823A (en) | Cloning of the bioa, biod, biof, bioc and bioh genes of bacillus spraericus, vectors and transformed cells | |
JPS62155081A (ja) | 新規微生物およびそれを用いる醗酵法によるビオチンの製造法 | |
JPS61202686A (ja) | ビオチン生産性微生物 | |
JP4162383B2 (ja) | ホモグルタミン酸の生産に関与する遺伝子およびその使用 | |
US6277609B1 (en) | Method to produce biotin | |
KR101263597B1 (ko) | Fk506 또는 fk520의 생산능이 향상된 미생물 및 이를 이용한 fk506 또는 fk520의 대량 생산 방법 | |
KR102668767B1 (ko) | L-라이신 생산능이 향상된 코리네박테리움 글루타미쿰 변이주 및 이를 이용한 l-라이신의 생산 방법 | |
JP2003512832A (ja) | Latおよびcvm遺伝子の欠失した5rクラバム産生微生物 | |
KR20230175159A (ko) | L-라이신 생산능이 향상된 코리네박테리움 글루타미쿰 변이주 및 이를 이용한 l-라이신의 생산 방법 | |
KR20240000419A (ko) | L-라이신 생산능이 향상된 코리네박테리움 글루타미쿰 변이주 및 이를 이용한 l-라이신의 생산 방법 | |
CN117965325A (zh) | 一种产黄青霉菌株及其应用 | |
JP2003521883A (ja) | クロラムフェニコール生合成経路および遺伝子クラスターの特徴付け | |
JPS63173591A (ja) | ビオチン生合成酵素をコードするdna配列、これを含有するベクター、このベクターにより形質転換された細胞、およびこの細胞を用いたビオチンの製造法 | |
JPS6291185A (ja) | L−スレオニン生産を司る遺伝子を含む組換え体dnaおよびその製造法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050621 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050921 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20051031 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051221 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061128 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070227 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070416 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070528 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070717 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070803 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100810 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100810 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100810 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110810 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110810 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120810 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130810 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |